Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker (opens in new tab)

While the market's enthusiasm for one of Zealand's experimental drugs has cooled, investors are shifting focus to amylin-based medicines as a growth driver